The sleep testing technology will allow patients to use their smartphones for preliminary sleep apnea screening at home, potentially expanding access to diagnostic services.

Summary: EnsoData has acquired Resonea’s sleep testing technology, enabling the use of smartphones for preliminary sleep apnea screening at home. This acquisition aims to enhance home sleep diagnostics by adding acoustic flow and microphone data channels, providing breath-by-breath analysis during sleep. These new capabilities are expected to be available commercially in the US in 2024.

Key Takeaways:

  • Mobile-Based Screening: The acquisition allows EnsoData to offer preliminary sleep apnea screening through a smartphone app, aimed at increasing accessibility to diagnostic services without the need for proprietary medical hardware.
  • Diagnostic Capabilities: The new technology adds acoustic flow and microphone data channels, enabling breath-by-breath acoustic analysis during sleep to aid in identifying sleep apnea events.
  • Clinical Data for Physicians: By integrating these new data channels with existing PPG-based sleep testing, sleep physicians can access more comprehensive clinical data.

EnsoData has acquired sleep testing diagnostic technology from Resonea that enables a new way to pre-screen patients for sleep apnea and extends the diagnostic capabilities of home sleep testing.

With this acquisition, EnsoData adds two new channels to its platform—an acoustic flow channel and a microphone channel—which will utilize a US Food and Drug Administration (FDA)-cleared mobile app to record auditory data during sleep, transfer that data to the cloud, and enable a breath-by-breath acoustic analysis of respiratory flow and snoring to identify events indicative of sleep apnea or other disorders. 

Using the patient’s existing smartphone, without any proprietary medical hardware, the microphone and acoustic flow respiration signals are leveraged to enable a mobile-first approach to pre-screening patients for sleep apnea.

In the diagnostic setting, sleep physicians will have access to these two channels for sleep studies conducted at home. By pairing an FDA-cleared pulse oximeter with mobile-based microphone and acoustic flow, clinicians can complement the analysis and reporting available in EnsoSleep PPG to obtain a greater depth and breadth of clinical data. Physicians can leverage this new output to provide more personalized sleep apnea diagnoses and tailored patient experiences in starting treatment.

“We are very excited to bring both acoustic flow and microphone data to the sleep community to expand the clinical data available for the health systems and providers utilizing PPG-based sleep testing,” says Justin Mortara, EnsoData CEO, in a release. “This is another step toward simplifying access to sleep care, helping to get more patients with sleep disorders diagnosed and ultimately connected with therapy. As a leader in healthcare AI solutions, EnsoData’s device-agnostic approach using pulse oximeters (PPG) and now smartphones supports our strategy to deploy flexible solutions that can easily scale to address the unmet clinical needs for sleep testing in the US and globally.”

Initial US commercial availability of the new capabilities is expected within 2024. 

Photo 59869436 © Monkey Business Images |